Hypereosinophilic syndrome: Long‐term remission following allogeneic stem cell transplant in spite of transient eosinophilia post‐transplant

• Published in: American journal of hematology Vol. 78; no. 1; pp. 33 - 36
• Main Authors: Cooper, Maureen A., Akard, Luke P., Thompson, James M., Dugan, Michael J., Jansen, Jan
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2005; Wiley-Liss
• Subjects: Adult; allogeneic stem cell transplant; Biological and medical sciences; Bone Marrow Transplantation - adverse effects; Cyclophosphamide - administration & dosage; Cyclophosphamide - therapeutic use; Cytarabine - administration & dosage; Cytarabine - therapeutic use; Dose-Response Relationship, Drug; Eosinophilia - drug therapy; Eosinophilia - etiology; Eosinophilia - physiopathology; Hematologic and hematopoietic diseases; HES; Humans; hypereosinophilic syndrome; Hypereosinophilic Syndrome - surgery; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Interleukin-5 - blood; long‐term remission; Male; Medical sciences; Other diseases. Hematologic involvement in other diseases; Postoperative Period; Remission Induction; Time Factors; transient eosinophilia; Transplantation, Homologous; Urticaria - drug therapy; Urticaria - etiology; Urticaria - physiopathology; Hematology; Homograft; Hemopathy; Transplantation; Eosinophilia; Long term; Transitory; Treatment; Surgery; HES; Graft; Remission; long-term remission; allogeneic stem cell transplant; transient eosinophilia; Hypereosinophilic syndrome
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.20214

A 38‐year‐old male with progressive myeloproliferative variant of hypereosinophilic syndrome (HES) underwent allogeneic bone marrow transplantation from a matched unrelated donor. The preparative regimen consisted of TBI, cytarabine, and cyclophosphamide. The graft was T‐cell‐depleted. The patient had slow, but complete, hematologic recovery, and all cells were shown by VNTR analysis to be of donor origin. Five months after transplant, the patient developed prominent eosinophilia (peak 4.1 × 109/L) with dermatographism and very high IL‐5 levels. Eosinophils isolated to purity by cell sorting were all of donor origin. Mild increase in immunosuppression led to a normalization of eosinophil count after about 6 months. The patient is now 6 years after transplant, off all medications, and without evidence of disease. Allogeneic stem‐cell transplantation is a potentially curative therapy for HES. Am. J. Hematol. 78:33–36, 2005. © 2004 Wiley‐Liss, Inc.